Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

82 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Chemotherapy acutely impairs neurovascular and hemodynamic responses in women with breast cancer.
Sales ARK, Negrão MV, Testa L, Ferreira-Santos L, Groehs RVR, Carvalho B, Toschi-Dias E, Rocha NG, Laurindo FRM, Debbas V, Rondon MUPB, Mano MS, Hajjar LA, Hoff PMG, Filho RK, Negrão CE. Sales ARK, et al. Among authors: mano ms. Am J Physiol Heart Circ Physiol. 2019 Jul 1;317(7):H1-H12. doi: 10.1152/ajpheart.00756.2018. Epub 2019 Apr 19. Am J Physiol Heart Circ Physiol. 2019. PMID: 31002284 Free article. Clinical Trial.
Metronomic chemotherapy in the neoadjuvant setting: results of two parallel feasibility trials (TraQme and TAME) in patients with HER2+ and HER2- locally advanced breast cancer.
Petry V, Gagliato DM, Leal AI, Arai RJ, Longo E, Andrade F, Ricci MD, Piato JR, Barroso-Sousa R, Hoff PM, Mano MS. Petry V, et al. Among authors: mano ms. Braz J Med Biol Res. 2015 May;48(5):479-85. doi: 10.1590/1414-431X20144354. Epub 2015 Mar 6. Braz J Med Biol Res. 2015. PMID: 25760024 Free PMC article. Clinical Trial.
Cost-effectiveness of ribociclib for premenopausal or perimenopausal women with HR+/HER2- advanced breast cancer: a Brazilian public health care system perspective.
Rosa DD, Magliano CADS, Simon SD, Amorim G, Reinert T, Landeiro L, Gagliato DM, Exman P, Argolo D, Guilgen G, Mano M, Testa L, Liedke P, Barroso R, Sasse M, Buehler AM. Rosa DD, et al. Ther Adv Med Oncol. 2022 Jun 20;14:17588359221100865. doi: 10.1177/17588359221100865. eCollection 2022. Ther Adv Med Oncol. 2022. PMID: 36339925 Free PMC article.
Clinical impact of adjuvant radiation therapy delay after neoadjuvant chemotherapy in locally advanced breast cancer.
Silva SB, Pereira AAL, Marta GN, de Barros Lima KML, de Freitas TB, Matutino ARB, de Azevedo Souza MCL, de Azevedo RGMV, de Viveiros PAH, da Silva Lima JM, Filassi JR, de Andrade Carvalho H, Piato JRM, Mano MS. Silva SB, et al. Among authors: mano ms. Breast. 2018 Apr;38:39-44. doi: 10.1016/j.breast.2017.11.012. Epub 2017 Dec 7. Breast. 2018. PMID: 29223797
Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer.
von Minckwitz G, Huang CS, Mano MS, Loibl S, Mamounas EP, Untch M, Wolmark N, Rastogi P, Schneeweiss A, Redondo A, Fischer HH, Jacot W, Conlin AK, Arce-Salinas C, Wapnir IL, Jackisch C, DiGiovanna MP, Fasching PA, Crown JP, Wülfing P, Shao Z, Rota Caremoli E, Wu H, Lam LH, Tesarowski D, Smitt M, Douthwaite H, Singel SM, Geyer CE Jr; KATHERINE Investigators. von Minckwitz G, et al. Among authors: mano ms. N Engl J Med. 2019 Feb 14;380(7):617-628. doi: 10.1056/NEJMoa1814017. Epub 2018 Dec 5. N Engl J Med. 2019. PMID: 30516102 Clinical Trial.
82 results